Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US8580768B2 · kind B2 · utility
5Cited by
6References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2011 |
| Grant date | Nov 12, 2013 |
| Priority date | — |
| Expiry date | Nov 18, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65031
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.